Predict your next investment

HemoShear Therapeutics company logo
HEALTHCARE | Drug Discovery
hemoshear.com

See what CB Insights has to offer

Founded Year

2008

Stage

Series A | Alive

Total Raised

$66.31M

Last Raised

$40M | 10 mos ago

About HemoShear Therapeutics

HemoShear Therapeutics discovers biological targets and advances drug programs to treat metabolic disorders with significant unmet patient need. Its proprietary drug discovery platform, REVEAL-TX, enables the company to create best-in-class, biological human disease models to uncover and explain the underlying mechanisms of disease, translate those discoveries into drug candidates, and predict which drug candidates will treat patients successfully.

HemoShear Therapeutics Headquarter Location

501 Locust Avenue Suite 301

Charlottesville, Virginia, 22902,

United States

434-872-0196

Latest HemoShear Therapeutics News

07:30 ET HemoShear Therapeutics Identifies Second Novel Target to Treat NASH Through Successful Collaboration with Takeda

Nov 16, 2021

Four-Year Collaboration Successfully Completed Resulting in Two Novel Drug Targets Advancing into Takeda's Discovery Portfolio News provided by Share this article Share this article CHARLOTTESVILLE, Va., Nov. 16, 2021 /PRNewswire/ -- HemoShear Therapeutics, Inc. announced today that a second target identified utilizing the company's REVEAL-Tx™ human disease modeling platform has been selected by Takeda Pharmaceutical Company Limited ("Takeda") for further drug discovery activities for nonalcoholic steatohepatitis (NASH). This marks the successful completion of HemoShear's exclusive collaboration with Takeda to discover novel targets and develop therapeutics for NASH. In accordance with the collaboration agreement executed in October 2017, HemoShear will receive an undisclosed milestone payment, and Takeda will assume drug discovery and development activities. "External partnerships are a key part of Takeda's drug discovery model and our collaboration with HemoShear has been important for advancing our liver disease portfolio," said Gareth Hicks, PhD, vice president & head of the Gastrointestinal Drug Discovery Unit at Takeda. "Our collaboration delivered on its promise to uncover disease drivers and identified and validated two novel drug targets that modulate these processes. We'll accelerate these promising targets to treat NASH towards the clinic and will continue our research efforts to develop much-needed treatments for severe liver diseases." "We are proud that our REVEAL-Tx™ platform, combining insights from our biological and computational models, has identified and validated two novel therapeutic approaches for NASH with Takeda," said Ryan Feaver, PhD, head of exploratory biology and program leader for NASH at HemoShear. "Takeda has been an incredible partner at every level, never wavering on the goal to discover first-in-class approaches for the treatment of NASH. We look forward to their team making great strides to develop promising drug candidates." HemoShear's REVEAL-Tx™ platform has been utilized to create a model of NASH that recapitulates hallmark features of liver fat build up, increased cell stress and inflammation, and extracellular matrix signaling that was published in the Journal of Clinical Investigation Insight . In addition, Nature Scientific Reports  published the company's research analyzing gene expression at various stages of nonalcoholic fatty liver disease. NASH, one of the leading causes of transplantation, is a serious, chronic liver disease that is estimated to impact over 16 million people in the United States alone. NASH is characterized by inflammation and excessive fat accumulation in the liver that may progress to fibrosis, cirrhosis, liver cancer, and eventually liver failure. There is currently no FDA approved therapeutic available for NASH and liver fibrosis patients. Under the terms of the original agreement , HemoShear received upfront payments and R&D funding, and Takeda received exclusive access to HemoShear's proprietary disease modeling platform to discover and develop best-in-class therapeutics for specific liver diseases. HemoShear is eligible to receive milestone payments of potentially $470 million plus royalties. HemoShear and Takeda are continuing their collaboration under a second agreement established in October 2020  to develop a new human tissue-based model of a rare liver disease using the REVEAL-Tx™ Platform. About HemoShear's REVEAL-Tx™ Platform Existing human experimental disease models do not reliably represent human biology. HemoShear has developed a transformational platform, REVEAL-Tx™, which applies principles of physiological blood flow to tissue from patients to recapitulate disease. REVEAL-Tx™ provides unprecedented insights into complex pathophysiological pathways by replicating human disease with great accuracy. HemoShear's human disease models, in combination with its advanced proprietary computational biology tools, identify novel treatment approaches and reduce risk of failure by enabling HemoShear's scientists to deeply interrogate disease pathways, test hypotheses and select meaningful targets in physiologically accurate disease conditions. About HemoShear Therapeutics HemoShear Therapeutics is a privately held clinical stage company developing treatments for rare metabolic disorders with significant unmet patient need. HemoShear's drug discovery platform, REVEAL-Tx™, enables the Company's scientists to create best-in-class, biologically relevant human disease models to uncover the underlying mechanisms of disease, translate those discoveries into drug targets, and select candidates that may treat patients successfully. In addition to the Company's proprietary rare disease programs, HemoShear has exclusive partnerships to identify novel therapeutic approaches in nonalcoholic steatohepatitis (NASH) and an undisclosed rare liver disease with Takeda , and in gout with Horizon Therapeutics . For more information visit www.HemoShear.com . SOURCE HemoShear Therapeutics

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing HemoShear Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

HemoShear Therapeutics is included in 1 Expert Collection, including Biopharmaceuticals.

B

Biopharmaceuticals

14,140 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

HemoShear Therapeutics Patents

HemoShear Therapeutics has filed 11 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Transcription factors
  • Fluid dynamics
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/18/2019

7/13/2021

Transcription factors, Clusters of differentiation, Fluid dynamics, Biotechnology, Cell biology

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

12/18/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

7/13/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Transcription factors, Clusters of differentiation, Fluid dynamics, Biotechnology, Cell biology

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

HemoShear Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

HemoShear Therapeutics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.